Medical insurance reimbursement ratio of Riluzole

In 2020, the original drug Riluzole has been approved by the State Food and Drug Administration for marketing in China, and has subsequently entered the scope of Class B medical insurance. Different regions have different reimbursement ratios, and the price after reimbursement may vary. The price of each box of 50mg*56 tablets may be around RMB 4,000, and this drug may be sold in domestic pharmacies or hospitals.

Riluzole was approved by the U.S. Food and Drug Administration (FDA) in 1995 for the treatment and management of amyotrophic lateral sclerosis (ALS) due to its neuroprotective properties, demonstrating that riluzole blocks voltage-dependent sodium channels in a dose-dependent manner. Although the exact mechanism of action of riluzole is still under investigation, numerous studies suggest that its effects stem from its ability to block glutamate release and enhance glutamate reuptake, thereby inhibiting glutamate-dependent signaling. It has been observed that oral administration of approximately 50 mg of riluzole per day has low toxicity in patients with amyotrophic lateral sclerosis, and the area under the curve of the 24-hour serum concentration is approximately 2000 ng/ml.

The Turkish version of Riluzole’s original drug specifications listed overseasThe price of 50mg*56 tablets per box may be around 1,200 RMB (the price may fluctuate due to exchange rates). There are also generic drugs produced in other countries. The price of a box of 50mg*30 tablets produced by an Indian pharmaceutical factory may be around RMB 1,300 (the price may fluctuate due to the exchange rate). The pharmaceutical ingredients of generic drugs are basically the same as those of domestic and foreign original drugs. For specific prices and drug information, please consult Yaode Medical Consultants.